Erratum: Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study


Page 91 states: Herpes zoster infections (n=7) were seen in the baricitinib 2 and 4 mg groups with similar frequency; none were visceral or disseminated. Herpes zoster distribution beyond the primary or adjacent dermatomes was seen in one patient (baricitinib 4 mg).